ReAlta Life Sciences raised $40 million to advance RLS-0071 (pegtarazimod), an FDA-designated orphan drug in Phase 2 clinical trials for the treatment of hypoxic-ischemic encephalopathy, a rare and devastating form of neonatal brain injury caused by oxygen deprivation at birth.
